Investigate the heterogeneity of colorectal cancer patients at the single-cell level prior to and subsequent to immunotherapy - Takeaways - MDSpire

Investigate the heterogeneity of colorectal cancer patients at the single-cell level prior to and subsequent to immunotherapy

  • By

  • Heng Zhao

  • Gao Wu

  • Junhong Zhao

  • Qianwen Wang

  • Wenkang Cheng

  • Jie Li

  • Jin Yang

  • May 4, 2026

  • 0 min

Share

  • 1

    Immune checkpoint inhibition (ICI) has improved outcomes for some colorectal cancer (CRC) patients, but response variability remains poorly understood.

  • 2

    Single-cell RNA sequencing revealed significant changes in immune cell populations in CRC patients before and after ICI treatment.

  • 3

    Responders to ICI exhibited strong cytotoxic T-cell activation, while non-responders showed persistent overexpression of the stress-response gene HSPA1B.

  • 4

    B cells from responders demonstrated increased TXNIP expression, indicating a potential link to pro-inflammatory responses in ICI therapy.

  • 5

    The study highlights the importance of understanding immune dynamics across tissues to enhance immunotherapy effectiveness in CRC.

Original Source(s)

Investigate the heterogeneity of colorectal cancer patients at the single-cell level prior to and subsequent to immunotherapy

  • by Heng Zhao, Gao Wu, Junhong Zhao, Qianwen Wang, Wenkang Cheng, Jie Li, Jin Yang

  • May 4, 2026

Related Content

Editorial: Innovative organoid co-culture systems for enhanced precision medicine in cancer and beyond

Dye-free versus dye-containing submucosal injection solutions in ESD for colorectal LST: a multi-center retrospective study on efficacy and safety

Multidimensional exploration of the relationship between gut microbiota and colorectal cancer: focus on clinical tumorigenesis and treatment